Zydus Lifesciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• Zydus Lifesciences Ltd reported a 5.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 20.7%.
• Its expenses for the quarter were up by 20.0% QoQ and 41.4% YoY.
• The net profit decreased 26.2% QoQ and decreased 34.9% YoY.
• The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 9.35 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zydus Lifesciences Ltd is a prominent player in the pharmaceutical industry, known for its extensive range of healthcare products and services. This company specializes in the development, manufacturing, and marketing of a wide array of pharmaceuticals, including generic drugs, branded formulations, and active pharmaceutical ingredients (APIs). Zydus Lifesciences is also engaged in research and development to innovate new therapies and solutions in the healthcare sector. While specific recent developments are not provided within the given data, the company is generally recognized for its commitment to improving healthcare accessibility and quality. It operates in a highly competitive industry, which is characterized by constant innovation and regulatory challenges.

Revenue

In Q1FY27, Zydus Lifesciences Ltd reported a total income of ₹8123.10 crores, marking a 5.2% increase from the previous quarter (Q4FY26) where it was ₹7721.20 crores. Compared to the same quarter in the previous year (Q1FY26), the total income rose by 20.7% from ₹6728.60 crores. This growth in revenue indicates a positive trajectory in the company’s income-generating capabilities over both the quarterly and annual periods. The company's ability to enhance its revenue streams over the past year reflects its market performance and potential expansion in its sales or service offerings.

Profitability

Profitability metrics for Zydus Lifesciences Ltd in Q1FY27 indicate a decline compared to previous periods. The Profit Before Tax (PBT) was ₹1306.60 crores, which represents a decrease of 21.3% from ₹1659.70 crores in Q4FY26 and a 32.0% decrease from ₹1920.60 crores in Q1FY26. Similarly, the Profit After Tax (PAT) stood at ₹990.20 crores, down by 26.2% from ₹1341.00 crores in the preceding quarter and 34.9% from ₹1521.00 crores in the same quarter last year. The Earnings Per Share (EPS) also declined, with a value of ₹9.35 in Q1FY27, reflecting a 26.1% drop from ₹12.65 in Q4FY26 and a 35.9% decrease from ₹14.58 in Q1FY26. These figures highlight a downward trend in profitability over both quarterly and yearly comparisons.

Operating Metrics

The total expenses for Zydus Lifesciences Ltd in Q1FY27 were ₹6798.30 crores, showing a 20.0% increase from ₹5664.00 crores in Q4FY26 and a 41.4% rise from ₹4808.00 crores in Q1FY26. The tax expense for the quarter was ₹354.20 crores, which increased by 11.2% from the previous quarter's ₹318.40 crores but decreased by 18.4% from ₹434.00 crores in the same quarter of the previous year. The increase in total expenses suggests a significant change in the cost structure or scale of operations, impacting the overall financial metrics. While the tax expenses have shown mixed results on a quarterly and yearly basis, they play a crucial role in the final profitability figures of the company.